78 results
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
Item 3. Legal Proceedings 106 Item 4. Mine Safety Disclosures 106 PART II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters … or prevented. Our clinical trials may fail to adequately demonstrate the safety and efficacy of any of our product candidates and if this happens
8-K
CRBU
Caribou Biosciences Inc
4 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4:05pm
data will not ultimately be predictive of the safety and efficacy of the Company’s product candidates or that clinical outcomes may differ as patient
8-K
EX-99.1
CRBU
Caribou Biosciences Inc
4 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4:05pm
initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases … by year-end 2024.
“CB-010 has demonstrated encouraging initial safety and efficacy in patients with relapsed or refractory B cell non-Hodgkin
8-K
EX-99.2
CRBU
Caribou Biosciences Inc
4 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4:05pm
characteristics, safety, efficacy, therapeutic effects, and potential advantages of our product candidates; the expected timing or likelihood of regulatory filings … is made as to the safety or effectiveness of these product candidates for the therapeutic uses for which such product candidates are being
8-K
EX-99.1
80ofne arfmib
11 Mar 24
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:22pm
8-K
EX-99.1
3cyjtnhmieg facz6wz
8 Jan 24
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8:00am
8-K
8seigwur5tk1ia9adq
8 Jan 24
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8:00am
8-K
EX-99.1
n8rdnvpa3yyf2vwy
12 Dec 23
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
4:05pm
8-K
u4u2gq3oizd9ki8
12 Dec 23
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
4:05pm
8-K
EX-99.1
ia51hj2xh7iz35siv
7 Nov 23
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
4:02pm
8-K
EX-99.1
f3q25 v3c
18 Oct 23
Regulation FD Disclosure
8:02am
8-K
EX-99.1
1l8okyss26nw2q7s
8 Aug 23
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
4:03pm
8-K
EX-1.1
m7rahgll2c 2sz
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
424B5
4pgcj2z5
14 Jul 23
Prospectus supplement for primary offering
5:31pm
8-K/A
EX-99.1
bf1qyavpx5px7w3ezn
14 Jul 23
Other Events
4:22pm
424B5
vwx70q0 c7x3hlpec09
13 Jul 23
Prospectus supplement for primary offering
4:56pm